Translocator protein (18 kDa), known
as TSPO, is a recognized biomarker
of neuroinflammation. Radioligands with PET accurately quantify TSPO
in neuroinflammatory conditions. However, the existence of three human
TSPO genotypes that show differential affinity to almost all useful
TSPO PET radioligands hampers such studies. There is an unmet need
for genotype-insensitive, high-affinity, and moderately lipophilic
TSPO ligands that may serve as leads for PET radioligand development.
To address this need, we varied the known high-affinity TSPO ligand
(l)-N,N-diethyl-2-methyl-3-(2-phenylquinolin-4-yl)propanamide
in its aryl scaffold, side chain tether, and pendant substituted amido
group while retaining an N-methyl group as a site
for labeling with carbon-11. From this effort, oxygen-tethered N-methyl-aryloxypropanamides emerged as new high-affinity
TSPO ligands with attenuated lipophilicity, including one example
with attractive properties for PET radioligand development, namely N-methyl-N-phenyl-2-{[2-(pyridin-2-yl)quinolin-4-yl]oxy}propanamide
(22a; rat Ki = 0.10 nM; human
TSPO genotypes Ki = 1.4 nM; clogD = 4.18).